Scarica l'app Stockscreener
30.34
2.78%
0.82
Dopo l'orario di chiusura:
30.34
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Arcus Biosciences (RCUS) officer eyes sale after June plan trades - Stock Titan
Arcus Biosciences (RCUS) Stock Looks Strong On Returns But Stretched On Sales - Sahm
Investigation launched into Arcus Biosciences o... - Pluang
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm - PR Newswire
Handelsbanken Fonder AB Takes $1.20 Million Position in Arcus Biosciences, Inc. $RCUS - MarketBeat
What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders - webull.com
Arcus Biosciences Inc (RCUS) (Q2 2026) Earnings Call Highlights: - GuruFocus
Arcus Biosciences (RCUS) Advances 2.15% as Oncology Pipeline Momentum BuildsEMA Signal - vinanet.vn
Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain? - Sahm
Arcus Biosciences (RCUS) Gains Nearly 2% as Shares Trade Near Key Resistance at $30.90Call Dominated - vinanet.vn
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% Upside - TradingView
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard? - Yahoo Finance
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - finance.yahoo.com
Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript - The Globe and Mail
(RCUS) Volatility Zones as Tactical Triggers - Stock Traders Daily
A New Arcus Employee Receives Options With a $28.72 Exercise Price - Stock Titan
BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Maintains Target Price $29 - Moomoo
Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating - Yahoo Finance
HC Wainwright Issues Optimistic Forecast for RCUS Earnings - MarketBeat
Goldman Sachs Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Raises Target Price to $42 - Moomoo
Arcus Biosciences Q2 Earnings Call Highlights - MarketBeat
Arcus Biosciences (RCUS) Stock Gets Fair Value Bump After Casdatifan Optimism - Yahoo Finance
A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $42 to $45 - moomoo.com
Arcus Biosciences (NYSE: RCUS) gets 24.7% ownership from Gilead - Stock Titan
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), NewAmsterdam Pharma Company (NAMS) and Revolution Medicines (RVMD) - The Globe and Mail
Arcus Biosciences Inc (RCUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ocular Therapeutix (OCUL) and Arcus Biosciences (RCUS) - The Globe and Mail
RCUS Maintained by Wells Fargo -- Price Target Raised to $26.00 - GuruFocus
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $26.00 - MarketBeat
RCUS Maintained by Wedbush -- Price Target Raised to $43.00 - GuruFocus
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.25, Implies 38% Upside - TradingView
Wedbush Adjusts Price Target on Arcus Biosciences to $43 From $41, Maintains Outperform Rating - Yahoo Finance
Arcus Biosciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Arcus Biosciences Inc (RCUS) News, Articles, Events & Latest Updates - Stocktwits
RCUS Looks 129.7% Overvalued on GF Value™ - GuruFocus
RCUS SWOT Analysis: Financial Struggles and Competitive Pressures Revealed in 10-Q Filing - GuruFocus
Earnings call transcript: Arcus Biosciences tops Q2 2026 estimates, shares rise - Investing.com Canada
Arcus Biosciences (NYSE:RCUS) Releases Earnings Results, Beats Expectations By $0.17 EPS - MarketBeat
Arcus Biosciences, Inc. 2026 Q2ResultsEarnings Call Presentation (NYSE:RCUS) 2026-08-05 - Seeking Alpha
Arcus Q2 2026 slides: casdatifan leads oncology, immunology push - Investing.com
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
RCUS: Casdatifan advances as a potential RCC backbone therapy, supported by robust cash and key data ahead - TradingView
Arcus Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (RCUS) Arcus Biosciences, Inc. Reports Q2 Revenue $41.0M - marketscreener.com
Arcus Biosciences Q2 revenue falls sharply on lower license income - TradingView
Arcus Biosciences 2Q 2026: Revenue $41M, EPS ($0.72) — 10-Q Summary - TradingView
RCUS: Advanced casdatifan in ccRCC, secured new partnerships, and maintained strong cash runway - TradingView
Arcus Biosciences reports Q2 2026 results: $41M revenue, $775M cash, $91M net loss - TradingView
Arcus Biosciences (NYSE: RCUS) posts Q2 loss, ends Gilead options - Stock Titan
Arcus Biosciences, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Arcus Biosciences earnings in focus as kidney cancer drug advances By Investing.com - Investing.com Nigeria
Arcus Biosciences earnings in focus as kidney cancer drug advances - Investing.com
Dimensional Fund Advisors LP Has $30.80 Million Stake in Arcus Biosciences, Inc. $RCUS - marketbeat.com
Arcus Biosciences earnings beat by $0.18, revenue topped estimates - Investing.com Canada
Earnings To Watch: Arcus Biosciences Inc (RCUS) Q2 2026 -- GF Va - GuruFocus
Arcus Biosciences Inc expected to post a loss of 90 cents a shareEarnings Preview - TradingView
Arcus Biosciences, Inc. Stock 12‑Month Price Target Cut to $37.17, Implies 32% Upside - TradingView
BofA Securities Adjusts Arcus Biosciences Price Target to $29 From $25 - Moomoo
Arcus Biosciences, Inc. $RCUS Shares Acquired by Renaissance Technologies LLC - MarketBeat
Price-Driven Insight from (RCUS) for Rule-Based Strategy - Stock Traders Daily
How Investors May Respond To Arcus Biosciences (RCUS) Expanding ARC-20 With New Kidney Cancer Combo - Sahm
Arcus Biosciences, Inc. (RCUS) Stock Analysis: Unveiling Near-Term Growth Potential with a 30% Upside - DirectorsTalk Interviews
Arcus Biosciences (RCUS) Q1 2026 Earnings: Wider EPS Loss of -$1.02 Offsets 6.81% Stock RallyShare Repurchase Impact - vinanet.vn
Arcus Biosciences (RCUS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
1.21%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):